

# An international study to assess the effects of strontium ranelate in the reduction of bone loss around the metal implant, in patients with hip prosthesis

<b>Submission date</b> 31/05/2011	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 04/08/2011	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 21/04/2020	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

## Contact information

### Type(s)

Scientific

### Contact name

Prof Maria Luisa Brandi

### Contact details

AOUC-D.A.I Ortopedia S.O.D  
Malattie del Metabolismo Minerale ed Osseo CTO  
Azienda Ospedaliero  
Universitaria CareggiLargo Pelagi 1  
Firenze  
Italy  
50139

## Additional identifiers

### Clinical Trials Information System (CTIS)

2010-020215-36

### Protocol serial number

CL3-12911-037

# Study information

## Scientific Title

A prospective, controlled, double blind, international study to assess the effects of strontium ranelate vs placebo on the reduction of periprosthetic bone loss in patients with total hip arthroplasty

## Study objectives

To demonstrate the efficacy of strontium ranelate in the reduction of bone loss in patients with total hip arthroplasty

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

## Study design

Prospective placebo-controlled randomised double-blind study

## Primary study design

Interventional

## Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Periprosthetic bone loss / total hip arthroplasty

## Interventions

Intervention (63 participants) - One sachet of 2g of strontium ranelate daily

Placebo (63 participants)

Total duration of intervention is 12 months.

## Intervention Type

Drug

## Phase

Not Applicable

## Drug/device/biological/vaccine name(s)

Strontium ranelate

## Primary outcome(s)

The relative change of periprosthetic bone mineral density (BMD) in region 7 of Gruen after total hip arthroplasty over 12 months

## Key secondary outcome(s))

1. The relative change of other regions of Gruen over 12 months
2. Safety over 12 months

**Completion date**

30/04/2013

## Eligibility

**Key inclusion criteria**

1. Caucasian male or postmenopausal women
2. Age less than or equal to 50 years
3. Patients with conventional primary total hip arthroplasty, cementless femoral stem and primary coxarthrosis as indication for total hip arthroplasty

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Total final enrolment**

96

**Key exclusion criteria**

1. Short femoral stem
2. Any perioperative complication
3. Patient with inflammatory arthropathy
4. Impossibility to perform Dual-emission X-ray absorptiometry (DXA)
5. Increase risk or history of venous thromboembolism (VTE)
6. Known hypersensitivity or contraindication to the study drug or Calperos D3®
7. Concomittant treatments likely to interfere with bone metabolism

**Date of first enrolment**

01/05/2011

**Date of final enrolment**

30/04/2013

## Locations

**Countries of recruitment**

Belgium

Brazil

Germany

Italy

Spain

**Study participating centre**  
AOUC-D.A.I Ortopedia S.O.D  
Firenze  
Italy  
50139

## Sponsor information

**Organisation**  
Institut de Recherches Internationales Servier (France)

**ROR**  
<https://ror.org/034e7c066>

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Institut de Recherches Internationales Servier (France)

## Results and Publications

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com> if a Marketing Authorisation has been granted after 1st January 2014.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>				No	No
<a href="#">Basic results</a>			21/04/2020	No	No

